Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Novel Feeder Cell Line Dramatically Expands NK Cell Production

Novel Feeder Cell Line Dramatically Expands NK Cell Production

Published

on

Allogeneic natural killer (NK) cells appear promising as an adoptive cell therapy (ACT) that targets cancer. They’re limited, however, by production methods that can’t readily produce these cells in therapeutically relevant quantities.

Researchers led by Sang-Ki Kim, DVM, PhD, professor, Kongju National University in Korea, and CSO at Vaxcell Bio, along with Seung-Hwan Lee, PhD, professor, University of Ottawa, appear to have solved that bottleneck with an engineered version of the feeder cell line known as ARH-77, a B-lymphoblast cell line that stimulates NK cells. Even in its unmodified form, ARH-77 cells expanded NK cells extracted from peripheral blood samples 681-fold after 28 days. In contrast, K562, the cell line typically used, enabled 155-fold expansion during that time.

That expansion pales in comparison to that of the engineered cell line. The now-modified ARH-77 cells, modified to express four specific stimulatory ligands, expanded NK cells by 101,241-fold in 28 days. Making the same modifications to the K562 cells, however, improved production only 4.4-fold. In each of the cell lines, purity and cytotoxicity were considered equivalent.

Kim, Lee, and colleagues chose the ligands B7-H6, CD137L, IL-15, and IL-15Rα to provide multi-axis stimulation to enhance NK cell activation and proliferation as well as to enhance persistence. For example, B7-H6 stimulates production and exhibits early cytotoxic benefits, but those benefits dissipated by week four. CD137L appears to compensate for that attenuation, the scientists report. Notably, the feeder performance was consistent across donors.

While these ligands were more effective than other ligands the team considered, they stress that more work is needed to “formally establish the added value of each ligand.” They also want to evaluate the engineered ARH-77 in terms of in vivo persistence and anti-tumor activity against additional models. Large-scale manufacturing constraints also should be considered in future studies.

Because feeder cell performance is considered stable across the donor population, Kim and Lee suggest their engineered ARH-77 cell line may be a reliable option for NK cell expansion as therapeutic production scales up. As the scientists note, “These findings establish ARH-77 as a promising alternative feeder cell platform that could enhance the scalability, consistency, and potency of allogeneic NK cell manufacturing for clinical adoptive immunotherapy.”

 

The post Novel Feeder Cell Line Dramatically Expands NK Cell Production appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read